MMedication Read More Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric PushMay 2, 2026 Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
MMedication Read More Canada approves second generic version of OzempicMay 1, 2026 OTTAWA, May 1 (Reuters) – The Canadian health regulator said on Friday that it had approved Canada-based Apotex’s…
MMedication Read More Can Oral Ozempic and Label Expansions Revive NVO’s Near-Term Growth?April 29, 2026 Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic…
HHealthcare Read More Which Healthcare Giant Is the Better Bet?April 27, 2026 Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with…
MMedication Read More Lilly’s Foundayo hits 1,390 prescriptions in debut weekApril 17, 2026 April 17 (Reuters) – Eli Lilly’s newly launched obesity pill was prescribed 1,390 times in the U.S. as…
MMedication Read More Weight-Loss Injections Become Part of Pre-Wedding PreparationApril 7, 2026 HYDERABAD: Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest…
MMedication Read More As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices | Industry NewsMarch 31, 2026 Amid competition from cheaper generics, Danish drugmaker Novo Nordisk on Monday announced price cuts of up to…
MMedication Read More Ozempic Goes Generic —But Not in the USMarch 23, 2026 A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
MMedication Read More Coming Soon: ‘Wegovy HD’March 21, 2026 Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may…
MMedication Read More FDA sends letter to Novo Nordisk over potential GLP-1 side effectsMarch 13, 2026 The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
MMedication Read More FDA sends letter to Novo Nordisk over potential GLP-1 side effectsMarch 13, 2026 The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
HHealthcare Read More WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic DiseasesMarch 12, 2026 GENEVA, March 11, 2026 /PRNewswire/ — The WHO Foundation today announced an expanded collaboration with Novo Nordisk to support…